Page last updated: 2024-12-06

plerixafor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Plerixafor, also known as AMD3100, is a small molecule antagonist of the CXCR4 chemokine receptor. It was initially synthesized as a CXCR4 antagonist for the potential treatment of HIV infection. However, it has since been found to have significant effects on hematopoiesis. Plerixafor mobilizes hematopoietic stem cells (HSCs) from the bone marrow into the peripheral blood, allowing for easier collection and transplantation. This has made it a crucial tool for stem cell transplantation in patients with various hematologic malignancies, including leukemia and multiple myeloma. Plerixafor's mechanism of action involves blocking the interaction of CXCR4 with its natural ligand, stromal cell-derived factor-1 (SDF-1), which normally helps to retain HSCs within the bone marrow. By blocking this interaction, plerixafor disrupts the retention signal, causing HSCs to be released into the bloodstream. Plerixafor is administered intravenously and has a rapid onset of action, allowing for efficient stem cell mobilization. Its safety and efficacy have been demonstrated in numerous clinical trials, making it a standard of care in stem cell transplantation. Ongoing research focuses on exploring its potential in other areas, such as immune-mediated diseases and cancer therapy.'

plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65015
CHEMBL ID18442
CHEBI ID125354
SCHEMBL ID19038

Synonyms (100)

Synonym
11''''-xylyl bis-1,4,8,11-tetraazacyclotetradecane
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane(8hbr.2h2o)
1,1''''-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene
1,4,8,11-tetraazacyclotetradecanyl[4-(1,4,8,11-tetraazacyclotetradecanylmethyl)phenyl]methane
11-{4-[4,8, 11-1,4,8,11tetraaza-cyclotetradec-1-ylmethyl]-benzyl}-1,4,8,11tetraaza-cyclotetradecane-1,4,8-tricarboxylic acid tri-tert-butyl ester
bdbm50035696
HY-10046
gtpl844
1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & hippeastrum hybrid agglutinin( hha)
hha & amd-3100
gna & amd-3100
1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & galanthus nivalis agglutinin (gna)
1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane
plerixafor
1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]
1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
jm3100
amd 3100
bicyclam jm-2987
sid791
mozobil
jm 2987
amd3100 ,
NCGC00165722-01
1,1'-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane)
plerixaforum
jkl 169
sdz sid 791
1,1'-(benzene-1,4-diyldimethanediyl)bis(1,4,8,11-tetraazacyclotetradecane)
CHEBI:125354 ,
1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}
DB06809
L000104
CHEMBL18442 ,
D08971
mozobil (tn)
plerixafor (jan/usan/inn)
110078-46-1
FT-0660392
A809618
1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene octahydrochloride;plerixafor octahydrochloride
A25446
AKOS005266706
1,4,8,11-tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-
s915p5499n ,
plerixafor [usan:inn:ban]
unii-s915p5499n
1,1'-[1,4-phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane
FT-0673966
BCPP000104
NCGC00165722-02
CS-0451
S8030
BRD-K33240821-367-01-8
plerixafor [mi]
plerixafor [orange book]
plerixafor [mart.]
plerixafor [ema epar]
plerixafor [inn]
plerixafor [vandf]
plerixafor [usan]
1,1'-(1,4-phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane
plerixafor [jan]
plerixafor [who-dd]
SCHEMBL19038
J-503718
1,1'[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
YIQPUIGJQJDJOS-UHFFFAOYSA-N
AC-26837
AB01566900_01
1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane
mfcd05662218
sr-01000941593
SR-01000941593-1
EX-A1762
plerixafor (amd3100)
DTXSID70869520 ,
AS-42504
BCP02337
Q905835
CCG-269710
NCGC00165722-03
nsc-754363
amd-3100 (cxcr4)
nsc754363
nsc761388
nsc-761388
dtxcid60817494
1,1'-(1,4-phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane
1-((4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl)methyl)-1,4,8,11-tetrazacyclotetradecane
1,1'-(1,4-phenylenebismethylene)bis(1,4,8,11-tetraazacyclotetradecane)
plerixafor (mart.)
1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)
l03ax16
P2678
SY042073
EN300-187119
1-({4-[(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]phenyl}methyl)-1,4,8,11-tetraazacyclotetradecane
Z1889837352

Research Excerpts

Overview

Plerixafor is a bicyclam molecule that mobilizes CD34+ cells by reversibly disrupting CXCR4-CXCL12-supported HPC retention. The drug is a novel mobilizing agent of peripheral blood stem cells (PBSCs) in lymphoma and multiple myeloma (MM) patients whose cells mobilize poorly.

ExcerptReferenceRelevance
"RD-plerixafor is an effective, safe, and affordable strategy to ensure adequate PBSC mobilization in patients with MM or lymphoma who undergo ASCT."( Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
Alvarado-Navarro, DM; Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Del Carmen Tarín-Arzaga, L; Flores-Jiménez, JA; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; León, AG; Mejía-Jaramillo, G; Palomares-Leal, A; Salazar-Riojas, R; Sotomayor-Duque, G, 2019
)
1.5
"Plerixafor is a bicyclam molecule that mobilizes CD34+ cells by reversibly disrupting CXCR4-CXCL12-supported HPC retention."( Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors.
Castillo, C; Cid, J; Lozano, M; Romon, I, 2022
)
1.9
"Plerixafor is a recently introduced agent used to improve peripheral blood stem cell (PBSC) mobilization in patients with hematologic malignancies. "( Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.
Kogut, N; Krishnan, A; Nademanee, A; Shayani, S; Wang, S; Yuan, S, 2013
)
2.06
"Plerixafor is a novel mobilizing agent of peripheral blood stem cells (PBSCs) in lymphoma and multiple myeloma (MM) patients whose cells mobilize poorly. "( GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis.
Abdel-Rahman, F; Al Rawi, O; Hussein, A; Hussein, N; Jazar, HA; Saad, A; Sharma, S; Tuffaha, HW, 2014
)
2.1
"Plerixafor is a novel CXCR4 antagonist, licensed for autologous PBSC harvest (PBSCH) in patients who failed mobilization with granulocyte-colony-stimulating factor (G-CSF) alone."( Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.
Collins, GP; Eyre, TA; King, AJ; Pawson, R; Peniket, A; Rocha, V, 2014
)
1.41
"IV plerixafor is an effective strategy for mobilization with low failure rate and is well tolerated."( Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Laplant, B; Laumann, K; Mahlman, M; Miceli, T; Mikhael, J; Reeder, C; Stewart, AK; Winters, JL, 2014
)
1.18
"Plerixafor (Mozobil) is a CXCR4 antagonist that rapidly mobilizes CD34(+) cells into circulation. "( Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
Bahceci, E; Bolan, CD; Calandra, G; Childs, RW; Cook, L; Dunbar, C; Geller, N; Joo, J; Khuu, HM; Kurlander, R; Leitman, SF; Lundqvist, A; McCoy, JP; Ramos, C; Read, EJ; Smith, AL; Takahashi, Y; Tawab, A; Wong, S, 2013
)
2.04
"Plerixafor is a Food and Drug Administration-approved agent for improving peripheral blood stem cell (PBSC) mobilization in filgrastim (granulocyte-colony-stimulating factor [G-CSF])-stimulated patients with multiple myeloma and non-Hodgkin's lymphoma. "( Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
Kaniewski, M; Nademanee, A; Palmer, J; Shayani, S; Wang, S; Yuan, S, 2014
)
2.15
"Plerixafor is a novel drug used for mobilization purposes."( Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.
Jantunen, E; Varmavuo, V, 2014
)
2.57
"Plerixafor (AMD3100) is a small-molecule CXCR4 antagonist that prevents binding of SDF-1 to CXCR4 and has potential in prevention of cancer metastasis."( Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor.
Li, J; Oupický, D, 2014
)
1.34
"Plerixafor+pegfilgrastim is a simple, safe and effective HSPC mobilization regimen in myeloma and lymphoma, in both poor and good mobilizers, and is superior to pegfilgrastim alone."( Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Came, N; Demosthenous, L; Harrison, S; Herbert, KE; Link, E; Prince, HM; Ritchie, DS; Seymour, JF; Westerman, DA; Wiesner, G, 2014
)
2.57
"Plerixafor is an effective agent for mobilization; however, it is often reserved for salvage therapy because of its high cost."( Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma.
Banoff, K; Isola, L; Kim, SS; Renteria, AS; Steinberg, A, 2014
)
1.39
"Plerixafor is a more effective and less toxic mobilising agent than conventional chemotherapy (especially in heavily pretreated patients), with comparable subsequent outcome, and merits consideration as the first-line standard of care for stem cell mobilisation."( Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.
Bell, J; Braithwaite, B; Callaghan, T; Clark, JO; Clark, RE; Francis, S; McGinnity, N; Salim, R; Vithanarachchi, U, 2014
)
2.57
"Plerixafor (PL) is a chemokine receptor CXC Type 4-stromal-derived factor 1 inhibitor; its HSC-mobilizing properties are synergistic with G-CSF in poor mobilizing patients."( Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Assanelli, A; Bellio, L; Ciceri, F; Coppola, M; Corti, C; De Freitas, T; Gattillo, S; Malabarba, L; Malato, S; Marktel, S; Milani, R; Rizzo, L, 2015
)
2.58
"Plerixafor, is a novel agent, has been recently approved for mobilization of hematopoietic stem cells (HSCs)."( Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
Buyukasik, Y; Etgul, S; Goker, H, 2015
)
1.36
"Plerixafor is a SDF-1/CXCR4 axis blocker which can stimulate the release of stem cells from the bone marrow into blood circulation."( Plerixafor may treat intractable post-herpetic neuralgia.
Bao, M; Guan, Y; Guo, R; Li, X; Wang, Y; Wu, A; Xie, F; Yue, Y; Zhang, C, 2015
)
2.58
"Plerixafor is a novel CXCR4 antagonist that can promote mobilization."( Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.
Danylesko, I; Nagler, A; Sareli, R; Shem-Tov, N; Shimoni, A; Varda-Bloom, N; Yerushalmi, R, 2016
)
2.6
"Plerixafor is an effective haematopoietic stem cell mobilising agent in candidates for autologous transplantation, including patients with myeloma and lymphoma. "( Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.
Bell, J; Braithwaite, B; Clark, JO; Clark, RE; Haycox, A; Houten, R; Martin, AP; McLeod, C; Richards, S, 2016
)
2.19
"Plerixafor is a novel mobilizing agent approved for use in "poor mobilizer" patients with lymphoma and multiple myeloma; experience in systemic amyloidosis patients is limited."( Spontaneous splenic rupture following stem cell mobilization with G-CSF and plerixafor in AL amyloidosis.
Adami, F; Branca, A; Colpo, A; Lessi, F; Marino, F; Marson, P; Tison, T, 2016
)
1.39
"Plerixafor is an effective drug in patients who fail to mobilize with conventional strategy. "( Plerixafor for stem cell mobilization: the current status.
Bilgin, YM; de Greef, GE, 2016
)
3.32
"Plerixafor is an inhibitor of the CXCR4 chemokine receptor on hematopoietic progenitor cells, blocking its binding to SDF-1 (CXCL12) on bone marrow stroma."( No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice.
Billett, HH; Branch, C; Choi, E; Cui, MH; Mohandas, N; Shi, PA; Yazdanbakhsh, K, 2016
)
1.4
"Plerixafor is a selective antagonist of CXCR4 used for mobilization of hematopoietic stem cells (HSCs) for autologous stem cell transplantation (SCT) in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). "( A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.
Badel, K; Calandra, G; Hard, ML; MacFarland, R; Scarborough, R, 2010
)
2.1
"Plerixafor is a novel small molecule that inhibits CXCR4 binding to SDF-1, an interaction that is a principal regulator of hematopoietic stem cell trafficking. "( Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.
Cashen, AF, 2009
)
3.24
"Plerixafor (AMD3100) is a selective antagonist of a receptor expressed on haematopoietic stem cells. "( [Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
Gaarsdal, E; Hansen, PB, 2009
)
2.05
"Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). "( Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
Alexander, ET; Costa, LJ; Fouts, TV; Hogan, KR; Schaub, C; Stuart, RK, 2011
)
2.04
"Plerixafor is a new HSC mobilizing drug that antagonizes the binding of chemokine stromal-cell-derived factor-1alpha (SDF-1alpha) to CXC chemokine receptor 4 (CXCR4)."( Plerixafor: a peripheral blood stem cell mobilizer.
Gatesman, ML; Kessans, MR; Kockler, DR, 2010
)
2.52
"Plerixafor is an effective agent for mobilizing CD34+ HSC. "( Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Silva, M; Steinberg, M, 2010
)
3.25
"Plerixafor (AMD3100) is a new small molecular weight inhibitor of CXCR4, FDA approved to aid in stem cell mobilization."( Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct.
Kast, RE, 2010
)
1.31
"Plerixafor is a chemokine receptor 4 antagonist approved for use to mobilize stem cells for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma."( Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Armistead, PM; Gregory, KM; Rao, KV, 2010
)
2.52
"Plerixafor is a reversible CXCR4 antagonist that leads to a rapid release of hematopoietic stem and progenitor cells (HPSCs) from the bone marrow into the peripheral blood by interfering with the CXCL12-CXCR4 interaction. "( Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.
Galonska, L; Haas, R; Klärner, V; Kobbe, G; Saure, C; Schroeder, T; Weigelt, C, 2010
)
3.25
"Plerixafor is a novel drug used to improve mobilization of blood stem cells."( Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen, E; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Pyörälä, M, 2011
)
1.38
"Plerixafor is an effective and safe agent for stem cell collection in patients with NB."( Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma.
Cheung, IY; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Reich, L, 2012
)
2.54
"Plerixafor is a recently Food and Drug Administration (FDA)-approved CXCR4 antagonist, which is combined with granulocyte-colony-stimulating factor (G-CSF) to facilitate stem cell mobilization of lymphoma and myeloma patients."( Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Anderson, D; Flowers, CR; Gleason, C; Graiser, M; Hamilton, E; Kaufman, JL; Langston, A; Lechowicz, MJ; Li, J; Lonial, S; Prichard, JM; Renfroe, H; Vaughn, L; Waller, EK, 2011
)
2.06
"Plerixafor is a promising therapy for this condition."( The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
Aprikyan, A; Bolyard, AA; Dale, DC; Hsu, FJ; Kelley, ML; Makaryan, V; Westrup, EC; Wood, B, 2011
)
1.41
"Plerixafor (Mozobil®) is a CXCR4 chemokine receptor antagonist that is indicated for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the peripheral blood for collection and subsequent autologous stem-cell transplantation in patients who have non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) [US] and in patients who have lymphoma or MM and are poor mobilizers (EU). "( Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating, GM, 2011
)
3.25
"Plerixafor is an inhibitor of CXCR4 receptor."( [Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma].
Kramis-Cerezo, JL; Limón-Flores, A; Pérez-Lozano, U; Ramírez-Alvarado, A; Tripp-Villanueva, F; Vela-Ojeda, J,
)
1.13

Effects

Plerixafor (AMD3100) has been used in adults as a second line mobilizing agent. It has shown a potential to mobilize adequate CD34+HSCs numbers in this context. Plerixa for also has great potential for the treatment of hematological malignancies other than NHL and MM.

ExcerptReferenceRelevance
"Plerixafor has a different mechanism of action and has non-overlapping toxicities with G-CSF."( Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Andrea, N; Lee, SY; Mark Sloan, J; Quillen, K; Sanchorawala, V; Seldin, DC, 2014
)
2.57
"Plerixafor has also been used as a sole mobilization agent."( Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors.
Castillo, C; Cid, J; Lozano, M; Romon, I, 2022
)
1.9
"Plerixafor (AMD3100) has been used in adults as a second line mobilizing agent."( Use of plerixafor for peripheral blood stem cell mobilization failure in children.
Aksu, T; Demir, HA; Emir, S; Kara, A; Özgüner, M; Tunç, B, 2014
)
1.58
"Plerixafor has shown a potential to mobilize adequate CD34+HSCs numbers in this context."( Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumo
Athanasopoulos, A; Daladimos, T; Dimitriadis, G; Gekas, C; Kosmas, C; Lydakis, D; Magiorkinis, E; Miltiadous, C; Mylonakis, N; Zilakos, M; Ziras, N, 2014
)
2.57
"Plerixafor has a different mechanism of action and has non-overlapping toxicities with G-CSF."( Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Andrea, N; Lee, SY; Mark Sloan, J; Quillen, K; Sanchorawala, V; Seldin, DC, 2014
)
2.57
"Plerixafor has been shown to significantly enhance stem cell mobilization but is very expensive."( Autologous Stem Cell Mobilization in the Age of Plerixafor.
Baker, J; Cooper, DL; Foss, F; Medoff, E; Patel, N; Perreault, S; Pratt, K; Seropian, SE; Wu, Y, 2016
)
1.41
"Plerixafor has been successfully used in clinical trails in patients with malignant lymphoma and multiple myeloma, where mobilization of stem cells with granulocyte colony-stimulating factor for leukapheresis and later stem cell transplantation were not possible."( [Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
Gaarsdal, E; Hansen, PB, 2009
)
1.33
"Plerixafor has also shown promising results in small studies enrolling patients with Hodgkin's lymphoma."( Plerixafor: a peripheral blood stem cell mobilizer.
Gatesman, ML; Kessans, MR; Kockler, DR, 2010
)
2.52
"Plerixafor also has great potential for the treatment of hematological malignancies other than NHL and MM, and non-hematological malignancies, and, eventually, several other diseases depending on the CXCL12-CXCR4 interaction."( Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq, E, 2010
)
1.33
"Plerixafor has been recently introduced combined with G-CSF in patients who mobilize poorly."( Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.
Fruehauf, S; Jantunen, E, 2011
)
1.09
"Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. "( Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Alamos, SM; Antoniazzi, F; Arcaini, L; Balzarotti, M; Bonfichi, M; Farina, L; Guggiari, E; Laszlo, D; Martinelli, G; Morra, E; Rizzi, S; Rossi, G; Todisco, E; Zilioli, VR, 2011
)
3.25
"Plerixafor has been recently introduced for clinical use to enhance PBSC mobilization and has been shown to be more effective than granulocyte-colony-stimulating factor (G-CSF) alone in patients with multiple myeloma or non-Hodgkin's lymphoma."( Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.
Jantunen, E; Lemoli, RM, 2012
)
1.43
"Plerixafor has been recently approved by the European Medicines Agency for adult patients who have failed other mobilization strategies. "( Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment.
Baragaño, M; Guggiari, E; Luksch, R; Madero, L; Massimino, M; Pardeo, M; Schiavello, E; Sevilla, J, 2012
)
2.08
"Plerixafor has orphan drug status for stem cell transplantation in cancer patients in the US and the EU."( Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791.
, 2007
)
2.5

Treatment

Treatment with plerixafor accelerated re-endothelialization and inhibited neointimal hyperplasia after endoth elial injury, indicating that it can to be used for endothelial regeneration.

ExcerptReferenceRelevance
"Plerixafor-treated subjects collected 7.8 × 10(6) CD34+ cells/kg; 22 (67%) collected in 1 day, while 11 (33%) required more than 1 day."( Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK, 2015
)
2.58
"Treatment with plerixafor accelerated re-endothelialization and inhibited neointimal hyperplasia after endoth elial injury, indicating that it can to be used for endothelial regeneration."( Plerixafor stimulates adhesive activity and endothelial regeneration of endothelial progenitor cells via elevating CXCR7 expression.
Hu, H; Jiang, C; Li, R; Ma, X; Wei, L; Zhao, J, 2020
)
2.34
"Treatment with plerixafor before and after ischemic clamping ameliorated kidney injury in a rat model of bilateral renal ischemia-reperfusion."( CXCR₄antagonism as a therapeutic approach to prevent acute kidney injury.
Fricker, SP; Gershenovich, M; Ivanova, Y; Ledbetter, S; MacFarland, RT; Zuk, A, 2014
)
0.74

Toxicity

Plerixafor inhibits the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1alpha) No acute adverse events were noted to be attributable to plerixa for administration.

ExcerptReferenceRelevance
" These findings suggest that gp120 is toxic to neurons even in the absence of the virus and that the toxic mechanism involves primarily activation of CXCR4 receptor."( The chemokine receptor CXCR4 and not the N-methyl-D-aspartate receptor mediates gp120 neurotoxicity in cerebellar granule cells.
Bachis, A; Mocchetti, I, 2004
)
0.32
" AMD070 was well tolerated, without serious adverse events."( Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Becker, S; Calandra, GB; Cao, YJ; Conley, J; Dunaway, SB; Flexner, C; Hendrix, CW; Kallungal, B; Klingman, KL; Lalama, C; MacFarland, RT; Park, JG; Snyder, S; Stone, ND; Tierney, C; Wiggins, IP, 2007
)
0.34
" Plerixafor administration was safe and no significant adverse events were recorded."( The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
Agis, H; Baccarani, M; Casadei, B; Curti, A; D'Addio, A; Dan, E; Douglas, K; Giudice, V; Kopetzky, G; Lemoli, RM; Motta, MR; Rizzi, S; Soutar, R; Taioli, S; Worel, N, 2011
)
1.63
" Accordingly, plerixafor seems to be safe and effective in germ cell tumor patients who have failed prior mobilization therapy."( Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.
Bogner, C; Bokemeyer, C; Fiedler, W; Frickhofen, N; Hübel, K; Isernhagen, J; Kilic, N; Kobold, S, 2011
)
2.17
" Common adverse events were diarrhoea, injection site erythema, perioral numbness, sinus tachycardia, headache, nausea, abdominal distention and injection site pain."( A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers.
Boss, C; Calandra, G; Childs, R; Cook, L; Geller, N; Goodwin, R; Hsieh, MM; Khuu, HM; Lemery, SJ; Rao, S; Smith, A; Theresa, D; Tisdale, J; Viano, JM, 2011
)
0.59
" Plerixafor administration was safe and no significant adverse events were recorded."( Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico, I; Coluzzi, S; Crescimanno, A; Di Nardo, E; Iacopino, P; Martino, M; Milone, G; Musso, M; Nuccorini, R; Olivieri, A; Ostuni, A; Pascale, S; Pavone, V; Rossini, B; Tedeschi, P, 2012
)
2.73
" There were no serious adverse events."( Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.
Calandra, GC; Holman, P; Horwitz, ME; Libby, E; Long, G; Schriber, JR, 2012
)
0.62
"CXCR4 antagonist plerixafor (AMD3100, 1,1'-bis-1,4,8,11-tetraazacyclotetradekan) alone or combination with adefovir (PMEA, 9-(2-phosphonylmethoxyethyl)adenine) safe and effective for treating FIV-infected cats."( Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats.
Balzarini, J; Egberink, H; Hartmann, K; Klein, D; Stengel, C,
)
0.72
" The most common adverse events (all grades) reported among older patients in the plerixafor group included diarrhea (41."( Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Bolwell, BJ; DiPersio, JF; Marulkar, S; Maziarz, RT; Micallef, IN; Nademanee, AP; Partisano, AM; Stadtmauer, EA; Stiff, PJ, 2013
)
0.9
" Transient gastrointestinal side effects of National Cancer Institute-grade 1 or 2 in severity were the most common adverse events."( Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.
Choi, J; Cross, SJ; Dallas, MH; Hartford, C; Jacobsen, J; Kang, G; Leung, W; Panetta, JC; Pillai, A; Shook, DR; Srinivasan, A; Sunkara, A; Triplett, BM, 2014
)
0.65
" Plerixafor+pegfilgrastim is a simple, safe and effective HSPC mobilization regimen in myeloma and lymphoma, in both poor and good mobilizers, and is superior to pegfilgrastim alone."( Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Came, N; Demosthenous, L; Harrison, S; Herbert, KE; Link, E; Prince, HM; Ritchie, DS; Seymour, JF; Westerman, DA; Wiesner, G, 2014
)
2.76
" The mtk-QSTR model was based on artificial neural networks (ANN), allowing the classification of compounds as toxic or non-toxic."( In silico assessment of the acute toxicity of chemicals: recent advances and new model for multitasking prediction of toxic effect.
Cordeiro, MN; Kleandrova, VV; Luan, F; Speck-Planche, A, 2015
)
0.42
" Plerixafor, a hematopoietic stem cell mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α), has been shown to be safe and efficacious in the mobilization of autologous PBSC in adults."( Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
Davies, S; Jodele, S; Mueller, M; Pinkard, S; Teusink, A, 2016
)
2.79
" No acute adverse events were noted to be attributable to plerixafor administration."( Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
Davies, S; Jodele, S; Mueller, M; Pinkard, S; Teusink, A, 2016
)
2.12
"Our findings suggest that plerixafor use in children is safe and efficacious for the mobilization of autologous PBSCs in subjects with relapsed malignancies or requiring stem cells for multiple transplants."( Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
Davies, S; Jodele, S; Mueller, M; Pinkard, S; Teusink, A, 2016
)
2.18
" The use of Filgrastim to mobilize large numbers of hematopoietic stem and progenitor cells into the circulation has been associated with severe adverse events in sickle cell patients."( Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.
André-Schmutz, I; Cavazzana, M; Couzin, C; Delville, M; Félix, T; Gabrion, A; Joseph, L; Lagresle-Peyrou, C; Lamhaut, L; Lefrère, F; Magnani, A; Magrin, E; Miccio, A; Plantier, C; Ribeil, JA; Romano, O; Sadek, H; Stanislas, A; Ternaux, B; Tréluyer, JM; Weber, L, 2018
)
1.92
"Plerixafor-based PBSC collection was safe and effective in our cohort and supports consideration as a primary mobilizing agent in children with malignancies."( A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders.
Abu-Arja, R; Bhunia, N; Dalal, JD; Goyal, RK; Kang, HJ; Lee, AC; Loeb, DM; Mehyar, LS; O'Brien, TA; Ozkaynak, MF; Rangarajan, HG; Roberts, CH; Shaw, PJ; Shenoy, SS; Stanek, JR; Stein, J; Strahlendorf, C, 2021
)
2.32

Pharmacokinetics

Plerixafor (AMD3100), a CXCR4 antagonist, administered either alone or with granulocyte colony-stimulating factor (G-CSF) resulted in dose-dependent mobilization of CD34(+) cells in the peripheral blood.

ExcerptReferenceRelevance
" The estimated terminal half-life ranged from 11."( Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Becker, S; Calandra, GB; Cao, YJ; Conley, J; Dunaway, SB; Flexner, C; Hendrix, CW; Kallungal, B; Klingman, KL; Lalama, C; MacFarland, RT; Park, JG; Snyder, S; Stone, ND; Tierney, C; Wiggins, IP, 2007
)
0.34
"Phase I pharmacokinetic (PK) and pharmacodynamic (PD) studies in healthy volunteers demonstrated that plerixafor (AMD3100), a CXCR4 antagonist, administered either alone or with granulocyte colony-stimulating factor (G-CSF), resulted in dose-dependent mobilization of CD34(+) cells in the peripheral blood."( Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Calandra, G; MacFarland, R; Smith, C; Stewart, DA, 2009
)
0.83
" This Phase 1 open-label study in healthy subjects was conducted to evaluate the pharmacokinetic characteristics of plerixafor in subjects with renal impairment."( A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.
Badel, K; Calandra, G; Hard, ML; MacFarland, R; Scarborough, R, 2010
)
0.87
" The clearance decreased and the elimination half-life increased significantly from dose level 1 to 3 (P < ."( Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.
Choi, J; Cross, SJ; Dallas, MH; Hartford, C; Jacobsen, J; Kang, G; Leung, W; Panetta, JC; Pillai, A; Shook, DR; Srinivasan, A; Sunkara, A; Triplett, BM, 2014
)
0.65
" Moreover, compound IIj had no observable cytotoxicity and displayed a favourable plasma stability in our preliminary pharmacokinetic study."( Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study.
Bai, R; Feng, A; Gurbani, S; Liang, Z; Salgado, E; Shim, H; Yoon, Y, 2017
)
0.46

Compound-Compound Interactions

Plerixafor, in combination with high-dose cytarabine and etoposide, was well tolerated in children and young adults with relapsed/refractory acute leukemias and MDS.

ExcerptReferenceRelevance
" Further studies are warranted to evaluate the effect of plerixafor in combination with chemomobilization on stem cell mobilization and collection on the first and subsequent days of apheresis, and its impact on resource utilization."( Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
Badel, K; Bensinger, WI; Bridger, G; Calandra, G; Dehner, C; Dugan, MJ; Gibney, C; Liesveld, J; Maziarz, RT; Nademanee, A, 2010
)
0.88
"), a new small-molecule inhibitor of the CXCR4 chemokine receptor, for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSC) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM)."( FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Booth, B; Brave, M; Ching Lin, S; Farrell, A; Fourie, J; He, K; Justice, R; Lee, SL; Ocheltree, T; Pazdur, R; Pope Miksinski, S; Saber, H; Tornoe, C; Yuan, W, 2010
)
0.36
" However, data are lacking regarding the feasibility and efficacy of just-in-time plerixafor in combination with chemotherapy and G-CSF."( Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Alousi, A; Anderlini, P; Champlin, R; Ciurea, S; de Lima, M; Hosing, C; Kebriaei, P; Khouri, I; Nieto, Y; Popat, U; Qazilbash, M; Rondon, G; Smith, VR, 2013
)
0.94
"To date, no prospective study on Plerixafor 'on-demand' in combination with chemotherapy and granulocyte colony-stimulating factor (G-CSF) has been reported."( Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Cupri, A; Di Marco, A; Di Martina, V; Leotta, S; Martino, M; Milone, G; Scalzulli, P; Schinocca, E; Spadaro, A; Spina, E; Tripepi, G, 2014
)
2.13
"AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-κB pathways."( AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells.
Bian, Z; Fang, X; Jiang, C; Jiang, W; Li, M; Tian, F; Wang, X; Zhang, H; Zhu, L, 2017
)
0.46
" A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) was performed to determine a tolerable and biologically active dose."( A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T, 2017
)
1.05
"Plerixafor, in combination with high-dose cytarabine and etoposide, was well tolerated in children and young adults with relapsed/refractory acute leukemias and MDS."( A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T, 2017
)
2.17
"" The present studies tested the hypothesis that in evoked pain, certain chemokine receptor antagonists (CRAs), given with a submaximal dose of morphine, would result in enhanced morphine potency."( Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management.
Adler, MW; Chen, X; Cowan, A; Eisenstein, TK; Geller, EB; Inan, S; Meissler, JJ; Rawls, SM; Tallarida, CS, 2020
)
0.56
" In the cold-water tail flick and formalin tests, significant increases of the antinociceptive effects of morphine were also observed when combined with CRAs."( Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management.
Adler, MW; Chen, X; Cowan, A; Eisenstein, TK; Geller, EB; Inan, S; Meissler, JJ; Rawls, SM; Tallarida, CS, 2020
)
0.56
" In patients with AML undergoing HCT, plerixafor given with the conditioning regimen appears safe and well tolerated."( Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies.
Allan, DS; Fulcher, J; Maganti, H; Sabloff, M; Shorr, R; Visram, A, 2020
)
2.27
" This phase 1 study evaluated the safety of myeloablative conditioning combined with plerixafor for allogeneic hematopoietic stem cell transplantation (HSCT)."( Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
Kato, J; Kikuchi, T; Koda, Y; Mori, T; Okamoto, S; Saburi, M; Sakurai, M; Shigematsu, N; Yamazaki, R, 2021
)
1.18
"The aim of the present study was to investigate the effect of the mobilization of EPCs by AMD3100 combined with G-CSF on wound healing in diabetic mice."( Mobilization of endothelial progenitor cells promotes angiogenesis after full thickness excision by AMD3100 combined with G-CSF in diabetic mice by SDF-1/CXCR4 axis.
Li, X; Lin, X; Wang, H,
)
0.13
" Cell invasion and metastasis-related factors decreased after AMD3100 combined with gemcitabine."( The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
Bian, W; Liu, JH; Liu, SG; Lv, HT; Wang, WB; Xing, L; Zhang, TF, 2021
)
0.62
"It is to explore, based on stromal cell derived factor 1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) signal axis, whether the electroacupuncture (EA) combined with bone marrow mesenchymal stem cells (BMSCs) transplantation can promote thin endometrium regeneration and improve endometrial receptivity, so as to further study its mechanisms underlying improvement of promoting BMSCs homing to repair thin endometrium."( [Electroacupuncture combined with bone marrow mesenchymal stem cell transplantation promotes repair of thin endometrium by regulating SDF-1/CXCR4 signaling].
Cheng, J; Hao, SN; Liu, JY; Shen, J; Xi, J; Xia, LJ; Xia, YB; Zhu, Q, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" E913 and its analogs are acid-resistant and orally bioavailable in rodents."( Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
Aoki, M; Fukushima, D; Habashita, H; Maeda, K; Mitsuya, H; Miyakawa, T; Sagawa, K; Shibayama, S; Tada, H; Yoshimura, K, 2001
)
0.31
" We suggest that non-peptide antagonists with, for example, improved oral bioavailability can be designed to mimic this interaction and thereby efficiently and selectively block the CXCR4 receptor."( Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.
Bridger, GJ; Gerlach, LO; Jakobsen, JS; Rosenkilde, MM; Schwartz, TW; Skerlj, RT, 2004
)
0.32
" Since TAK-652 is orally bioavailable and has favorable pharmacokinetic profiles in humans, it is considered a promising candidate for an entry inhibitor of HIV-1."( Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
Baba, M; Miyake, H; Okamoto, M; Takashima, K; Wang, X, 2007
)
0.34
" It was withdrawn from clinical trials owing to its lack of oral bioavailability and cardiotoxicity."( Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors.
Armand-Ugón, M; Batllori, X; Borrell, JI; Clotet, B; Clotet-Codina, I; Esté, J; Pérez-Nueno, VI; Pettersson, S; Puig de La Bellacasa, R; Rabal, MO; Ros-Blanco, L; Teixidó, J, 2008
)
0.35
" Second generation bicyclam mimics have the benefit of oral bioavailability but have, as yet, not proven successful in the clinic."( Recent patents regarding the discovery of small molecule CXCR4 antagonists.
Liotta, DC; Mosley, CA; Skudlarek, JW; Wilson, LJ; Wiseman, JM, 2009
)
0.35
" The compound shows an oral bioavailability of 25."( The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
Hamatake, M; Huang, W; Komano, J; Kumakura, S; Murakami, T; Okuma, K; Tanaka, R; Tanaka, Y; Toma, J; Yamamoto, N; Yamazaki, T; Yanaka, M, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In terms of a mechanism, we show that rhG-CSF bioavailability in the bone marrow is significantly improved in Alb-/- mice, compared to wild-type (WT) littermates, where rhG-CSF levels dramatically drop within a few hours of the injection."( Albumin Modifies Responses to Hematopoietic Stem Cell Mobilizing Agents in Mice.
Bonig, H; Danner, E; Wiercinska, E, 2019
)
0.51
" Although the CXCR4 antagonist (AMD3100) has been proposed as an attractive anti-GBM therapeutic target, it has poor pharmacokinetic properties, and unfavorable bioavailability has hampered its clinical implementation."( Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Ackermann, R; Alghamri, MS; Andjelkovic, AV; Apfelbaum, AA; Appelman, H; Banerjee, K; Barissi, M; Calinescu, A; Candolfi, M; Carney, S; Castro, MG; Comba, A; Edwards, MB; Faisal, SM; Gan, J; Gregory, JV; Jiménez, JA; Kadiyala, P; Lahann, J; Lawlor, ER; Lowenstein, PR; Martinez-Revollar, G; Mauser, A; McClellan, BL; Mujeeb, AA; Olin, MR; Schwendeman, A; Stamatovic, SM; Sun, Y; Taher, A; Thalla, R; Varela, ML, 2022
)
0.72

Dosage Studied

The current FDA-approved time interval between plerixafor dosing and apheresis initiation is approximately 11 hours, but this time interval is impractical for most care providers. To date, there is limited information on safe and effective dosing in dialysis-dependent patients.

ExcerptRelevanceReference
" The median systemic absorption after subcutaneous dosing was 87% (range, 67 to 106%)."( Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.
Bridger, G; Flexner, C; Fuchs, EJ; Giandomenico, C; Hendrix, CW; Henson, GW; MacFarland, RT; Redpath, E, 2000
)
0.31
" However, G-CSF mobilization can be associated with some significant side effects and requires a multi-day dosing regimen."( Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
Cashen, AF; Devine, SM; Lazarus, HM, 2007
)
0.34
" Using leukocytosis as a surrogate marker for CXCR4 inhibition, this dose-response relationship suggests that the doses used in this study were active in vivo, though not maximal, throughout the dosing interval."( Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Becker, S; Calandra, GB; Cao, YJ; Conley, J; Dunaway, SB; Flexner, C; Hendrix, CW; Kallungal, B; Klingman, KL; Lalama, C; MacFarland, RT; Park, JG; Snyder, S; Stone, ND; Tierney, C; Wiggins, IP, 2007
)
0.34
" To date, there is limited information on safe and effective dosing and administration of plerixafor in patients who are dialysis-dependent."( Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Armistead, PM; Gregory, KM; Rao, KV, 2010
)
2.02
" The following dosing cohorts were evaluated: 0·24 and 0·32 mg/kg (Cohort 1); 0·32 and 0·40 mg/kg (Cohort 2); and 0·40 and 0·48 mg/kg (Cohort 3)."( A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers.
Boss, C; Calandra, G; Childs, R; Cook, L; Geller, N; Goodwin, R; Hsieh, MM; Khuu, HM; Lemery, SJ; Rao, S; Smith, A; Theresa, D; Tisdale, J; Viano, JM, 2011
)
0.59
" Because AMD3100 is known to mobilize bone marrow derived stem cells (BMCs) in high concentrations, the optimal dosage (1."( Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
Assmann, G; Brunner, S; Fischer, R; Franz, WM; Gröbner, M; Hacker, M; Huber, B; Krieg, L; Mueller-Hoecker, J; Rischpler, C; Theiss, HD; Vallaster, M; Vanchev, Y; Wollenweber, T; Zaruba, MM, 2011
)
0.37
" Dosing of G-CSF and plerixafor was repeated until collection of ≥ 2 × 10(6) CD34+ cells/kg."( Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.
Calandra, GC; Holman, P; Horwitz, ME; Libby, E; Long, G; Schriber, JR, 2012
)
0.93
" According to the dosage of AMD3100, the medication group (n = 24) were divided into low dose group, high dose group, low dose control group, and high dose control group (each group n = 6)."( [Anti-angiogenesis effect of AMD3100 in oxygen-induced retinopathy mice].
Wang, LY; Xu, QY; Yuan, F; Yuan, YZ, 2012
)
0.38
"Plerixafor with granulocyte colony-stimulating factor (G-CSF) is effective for hematopoietic stem cell (HSC) mobilization in patients with non-Hodgkin Lymphoma and myeloma; however, labeling requires dosing 11 hours before apheresis."( Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Flowers, CR; Harvey, RD; Johnson, HR; Kaufman, JL; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; Nooka, A; Vaughn, L; Waller, EK, 2013
)
2.16
"The current FDA-approved time interval between plerixafor dosing and apheresis initiation is approximately 11 hours, but this time interval is impractical for most care providers."( Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.
Isola, LM; Miller, LK; Shi, PA, 2014
)
0.88
"Repeated dosing of drugs targeting G protein-coupled receptors can stimulate antagonist tolerance, which reduces their efficacy; thus, strategies to avoid tolerance are needed."( Biased antagonism of CXCR4 avoids antagonist tolerance.
Abdelkarim, H; Eby, JM; Gao, X; Gaponenko, V; Guite-Vinet, F; Heveker, N; Hitchinson, B; Lee, Y; Majetschak, M; Okamoto, Y; Shikano, S; Tarasova, NI; Volkman, BF; Ziarek, JJ, 2018
)
0.48
" The addition of plerixafor can be efficacious, though guidelines for repeat dosing are lacking."( Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
Gupta, GK; Hendrickson, JE; Perreault, S; Seropian, SE; Tormey, CA, 2021
)
1.27
"This quality improvement project was initiated to generate guidelines for repeat plerixafor dosing after retrospective evaluation of data in adult patients undergoing autologous peripheral blood stem cell mobilization and collection."( Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
Gupta, GK; Hendrickson, JE; Perreault, S; Seropian, SE; Tormey, CA, 2021
)
1.16
" In contrast, those in Groups 1A and 2A required additional plerixafor dosing and some mobilizations/collections were futile."( Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
Gupta, GK; Hendrickson, JE; Perreault, S; Seropian, SE; Tormey, CA, 2021
)
1.17
" We found that, in the same patient, higher plerixafor dosing was associated with higher fold increases in PB CD34+ count, but not necessarily higher absolute CD34+ counts."( Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease.
Boulad, F; Sadelain, M; Shi, PA; Yazdanbakhsh, K; Zhang, J, 2021
)
1.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
immunological adjuvantA substance that augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level. A classical agent (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contains bacterial antigens. It could also be endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Its mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy is related to its antigen-specific immunoadjuvanticity.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
C-X-C chemokine receptor type 4 antagonistAn antogonist that blocks C-X-C chemokine receptor type 4 (CXCR-4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
azamacrocycleA cyclic macromolecule containing one or more nitrogen atoms in place of carbon either as the divalent group NH for the group CH2 or a single trivalent nitrogen atom for the group CH.
crown amineCrown compounds containing only nitrogen as coordinating atom.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
azacycloalkane
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency31.62280.004023.8416100.0000AID485290
Fumarate hydrataseHomo sapiens (human)Potency0.41760.00308.794948.0869AID1347053
EWS/FLI fusion proteinHomo sapiens (human)Potency4.68590.001310.157742.8575AID1259256
polyproteinZika virusPotency0.41760.00308.794948.0869AID1347053
Bloom syndrome protein isoform 1Homo sapiens (human)Potency39.81070.540617.639296.1227AID2528
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-X-C chemokine receptor type 4Rattus norvegicus (Norway rat)IC50 (µMol)0.10800.10800.10800.1080AID408925
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
C-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)0.00010.00000.67366.6990AID381444; AID381445
C-X-C chemokine receptor type 4Homo sapiens (human)IC50 (µMol)0.82340.00030.28766.2000AID1316423; AID1383112; AID1383114; AID1473288; AID1477220; AID1501130; AID1586096; AID1595664; AID1595677; AID1630882; AID1702401; AID1702408; AID1742057; AID1742058; AID1902006; AID1902008; AID1902009; AID381443; AID393145; AID393146; AID408924; AID559976; AID559977; AID559978; AID559979; AID559980; AID559981; AID559982; AID559983; AID559984; AID559985; AID559986; AID559987; AID559988; AID559989; AID559990; AID707875
C-X-C chemokine receptor type 4Homo sapiens (human)Ki6.11370.01001.63929.7000AID357986; AID357987; AID357988; AID357989; AID357990; AID357991; AID357992; AID357993; AID357994; AID357995; AID357996; AID357997; AID357998; AID357999; AID358000; AID358001; AID358002; AID358003; AID358004; AID358005; AID358006; AID358007; AID358008; AID358009; AID358010; AID358011; AID358012; AID358013; AID358014; AID358015; AID358016; AID358017; AID358018; AID358019; AID358020; AID358021; AID358022; AID358023; AID358024; AID358025; AID358026; AID358027; AID358028
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Atypical chemokine receptor 3Homo sapiens (human)EC50 (µMol)140.00001.99532.19762.4000AID1852184
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-X-C chemokine receptor type 4Homo sapiens (human)EC (µMol)1.00000.01000.78001.0000AID1312693; AID1383871; AID1435831; AID1507420; AID1519443; AID1551312; AID1574049
C-X-C chemokine receptor type 4Homo sapiens (human)IC90 (µMol)0.91810.57220.82460.9711AID559976; AID559977; AID559978; AID559979; AID559980; AID559981; AID559982; AID559983; AID559984; AID559985; AID559986; AID559987; AID559988; AID559989; AID559990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (140)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisAtypical chemokine receptor 3Homo sapiens (human)
vasculogenesisAtypical chemokine receptor 3Homo sapiens (human)
cell adhesionAtypical chemokine receptor 3Homo sapiens (human)
negative regulation of cell population proliferationAtypical chemokine receptor 3Homo sapiens (human)
oculomotor nerve developmentAtypical chemokine receptor 3Homo sapiens (human)
receptor internalizationAtypical chemokine receptor 3Homo sapiens (human)
chemokine-mediated signaling pathwayAtypical chemokine receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAtypical chemokine receptor 3Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageAtypical chemokine receptor 3Homo sapiens (human)
positive regulation of mesenchymal stem cell migrationAtypical chemokine receptor 3Homo sapiens (human)
cell chemotaxisAtypical chemokine receptor 3Homo sapiens (human)
calcium-mediated signalingAtypical chemokine receptor 3Homo sapiens (human)
immune responseAtypical chemokine receptor 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAtypical chemokine receptor 3Homo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
blood vessel remodelingC-C chemokine receptor type 2Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell cytokine productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of type 2 immune responseC-C chemokine receptor type 2Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
humoral immune responseC-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of adenylate cyclase activityC-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATC-C chemokine receptor type 2Homo sapiens (human)
response to woundingC-C chemokine receptor type 2Homo sapiens (human)
regulation of vascular endothelial growth factor productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of angiogenesisC-C chemokine receptor type 2Homo sapiens (human)
sensory perception of painC-C chemokine receptor type 2Homo sapiens (human)
cellular homeostasisC-C chemokine receptor type 2Homo sapiens (human)
hemopoiesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of type II interferon productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of interleukin-2 productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionC-C chemokine receptor type 2Homo sapiens (human)
monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
T-helper 17 cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of eosinophil degranulationC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell differentiationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of alpha-beta T cell proliferationC-C chemokine receptor type 2Homo sapiens (human)
homeostasis of number of cells within a tissueC-C chemokine receptor type 2Homo sapiens (human)
regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell activationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicC-C chemokine receptor type 2Homo sapiens (human)
leukocyte adhesion to vascular endothelial cellC-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of immune complex clearance by monocytes and macrophagesC-C chemokine receptor type 2Homo sapiens (human)
inflammatory response to woundingC-C chemokine receptor type 2Homo sapiens (human)
neutrophil clearanceC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cold-induced thermogenesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of leukocyte tethering or rollingC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of NMDA glutamate receptor activityC-C chemokine receptor type 2Homo sapiens (human)
macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
regulation of macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of thymocyte migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of CD8-positive, alpha-beta T cell extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of astrocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of hematopoietic stem cell migrationC-C chemokine receptor type 2Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
immune responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 4Homo sapiens (human)
response to hypoxiaC-X-C chemokine receptor type 4Homo sapiens (human)
neuron migrationC-X-C chemokine receptor type 4Homo sapiens (human)
epithelial cell developmentC-X-C chemokine receptor type 4Homo sapiens (human)
dendritic cell chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
apoptotic processC-X-C chemokine receptor type 4Homo sapiens (human)
inflammatory responseC-X-C chemokine receptor type 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-X-C chemokine receptor type 4Homo sapiens (human)
neuron recognitionC-X-C chemokine receptor type 4Homo sapiens (human)
response to virusC-X-C chemokine receptor type 4Homo sapiens (human)
response to activityC-X-C chemokine receptor type 4Homo sapiens (human)
telencephalon cell migrationC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of cell adhesionC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cell migrationC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of vascular wound healingC-X-C chemokine receptor type 4Homo sapiens (human)
CXCL12-activated CXCR4 signaling pathwayC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of programmed cell deathC-X-C chemokine receptor type 4Homo sapiens (human)
myelin maintenanceC-X-C chemokine receptor type 4Homo sapiens (human)
endothelial cell differentiationC-X-C chemokine receptor type 4Homo sapiens (human)
symbiont entry into host cellC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of oligodendrocyte differentiationC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of viral processC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painC-X-C chemokine receptor type 4Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painC-X-C chemokine receptor type 4Homo sapiens (human)
regulation of calcium ion transportC-X-C chemokine receptor type 4Homo sapiens (human)
cardiac muscle contractionC-X-C chemokine receptor type 4Homo sapiens (human)
endothelial tube morphogenesisC-X-C chemokine receptor type 4Homo sapiens (human)
cellular response to cytokine stimulusC-X-C chemokine receptor type 4Homo sapiens (human)
cellular response to organonitrogen compoundC-X-C chemokine receptor type 4Homo sapiens (human)
cellular response to xenobiotic stimulusC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cold-induced thermogenesisC-X-C chemokine receptor type 4Homo sapiens (human)
response to tacrolimusC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of dendrite extensionC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of vasculature developmentC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of mesenchymal stem cell migrationC-X-C chemokine receptor type 4Homo sapiens (human)
response to ultrasoundC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of macrophage migration inhibitory factor signaling pathwayC-X-C chemokine receptor type 4Homo sapiens (human)
neurogenesisC-X-C chemokine receptor type 4Homo sapiens (human)
cell chemotaxisC-X-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-X-C chemokine receptor type 4Homo sapiens (human)
immune responseC-X-C chemokine receptor type 4Homo sapiens (human)
brain developmentC-X-C chemokine receptor type 4Homo sapiens (human)
calcium-mediated signalingC-X-C chemokine receptor type 4Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
scavenger receptor activityAtypical chemokine receptor 3Homo sapiens (human)
protein bindingAtypical chemokine receptor 3Homo sapiens (human)
coreceptor activityAtypical chemokine receptor 3Homo sapiens (human)
C-X-C chemokine receptor activityAtypical chemokine receptor 3Homo sapiens (human)
C-X-C chemokine bindingAtypical chemokine receptor 3Homo sapiens (human)
C-C chemokine receptor activityAtypical chemokine receptor 3Homo sapiens (human)
C-C chemokine bindingAtypical chemokine receptor 3Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-C chemokine receptor type 2Homo sapiens (human)
CCR2 chemokine receptor bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 2 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 12 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 2Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
virus receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
actin bindingC-X-C chemokine receptor type 4Homo sapiens (human)
G protein-coupled receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
protein bindingC-X-C chemokine receptor type 4Homo sapiens (human)
coreceptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
C-X-C chemokine receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine bindingC-X-C chemokine receptor type 4Homo sapiens (human)
ubiquitin protein ligase bindingC-X-C chemokine receptor type 4Homo sapiens (human)
myosin light chain bindingC-X-C chemokine receptor type 4Homo sapiens (human)
small molecule bindingC-X-C chemokine receptor type 4Homo sapiens (human)
C-X-C motif chemokine 12 receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
ubiquitin bindingC-X-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine receptor activityC-X-C chemokine receptor type 4Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeAtypical chemokine receptor 3Homo sapiens (human)
early endosomeAtypical chemokine receptor 3Homo sapiens (human)
plasma membraneAtypical chemokine receptor 3Homo sapiens (human)
clathrin-coated pitAtypical chemokine receptor 3Homo sapiens (human)
cell surfaceAtypical chemokine receptor 3Homo sapiens (human)
intracellular membrane-bounded organelleAtypical chemokine receptor 3Homo sapiens (human)
recycling endosomeAtypical chemokine receptor 3Homo sapiens (human)
external side of plasma membraneAtypical chemokine receptor 3Homo sapiens (human)
fibrillar centerC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytosolC-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
membraneC-C chemokine receptor type 2Homo sapiens (human)
dendriteC-C chemokine receptor type 2Homo sapiens (human)
neuronal cell bodyC-C chemokine receptor type 2Homo sapiens (human)
perikaryonC-C chemokine receptor type 2Homo sapiens (human)
perinuclear region of cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
lysosomeC-X-C chemokine receptor type 4Homo sapiens (human)
early endosomeC-X-C chemokine receptor type 4Homo sapiens (human)
cytoplasmC-X-C chemokine receptor type 4Homo sapiens (human)
lysosomeC-X-C chemokine receptor type 4Homo sapiens (human)
early endosomeC-X-C chemokine receptor type 4Homo sapiens (human)
late endosomeC-X-C chemokine receptor type 4Homo sapiens (human)
plasma membraneC-X-C chemokine receptor type 4Homo sapiens (human)
cell surfaceC-X-C chemokine receptor type 4Homo sapiens (human)
cell leading edgeC-X-C chemokine receptor type 4Homo sapiens (human)
cytoplasmic vesicleC-X-C chemokine receptor type 4Homo sapiens (human)
extracellular exosomeC-X-C chemokine receptor type 4Homo sapiens (human)
anchoring junctionC-X-C chemokine receptor type 4Homo sapiens (human)
protein-containing complexC-X-C chemokine receptor type 4Homo sapiens (human)
external side of plasma membraneC-X-C chemokine receptor type 4Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (322)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID279189Inhibition of HIV1 92TH594 infected CCR5+/CD4+/U87 cells to assess co-receptor tropism as luciferase activity2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.
AID1812648Anti-HIV activity against HIV-1 NL4.3 infected in PHA-stimulated human PBMC expressing CXCR-4 assessed as inhibition of virus-indued cytopathogenic effect measured after 10 days by ELISA
AID358040Antiviral activity against HIV1 NDK infected in U87.CD4 cells expressing human CXCR4 H281A mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1595675Antiviral activity against Human immunodeficiency virus 1 NL4-3 infected in human PBMC cells assessed as reduction in intracellular p24 level at 100 nM preincubated with cells 2 hrs followed by viral infection and measured after 24 hrs by ELISA2019European journal of medicinal chemistry, Jun-15, Volume: 172High affinity CXCR4 inhibitors generated by linking low affinity peptides.
AID73063Inhibitory concentration of compound against HIV-1 LAI strain in GHOST CXCR4 cell line2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID559952Displacement of [125I]SDF-1alpha form CXCR4 expressed in CHO cells at 0.1 to 1000 nmol/L by scintillation counting2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID559984Inhibition of Mab 12G5 binding to CXCR4 E275A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID525107Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID710726Inhibition of anti-CXCR4 mAbs clone 1D9 binding to CXCR4 in human SUPT1 cells incubated for 15 mins by FACS2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID1473288Displacement of [125I]CXCL12 from human CXCR4 expressed in HEK293 cell membranes after 1.5 hrs by Topcount method2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID45043Concentration of compound causing 50% death of uninfected cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID565586Inhibition of PIE7 binding to HIV1 3B gp41 at 1 uM after 30 mins by SPR assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
AID152970Effective concentration of compound against HIV-1 89.6 strain in PBMC cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID710733Antiviral activity against X4 HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of viral replication pre-incubated for 30 mins measured 5 days post infection by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID357995Displacement of [125I]12G5 antibody from transmembrane domain 5 of human CXCR4 V196A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID525111Antiviral activity against HIV 1 NL4.3 assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID358003Displacement of [125I]12G5 antibody from transmembrane domain 6 of human CXCR4 I259A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID710728Inhibition of anti-CXCR4 mAbs clone 173 binding to CXCR4 in human SUPT1 cells incubated for 15 mins by FACS2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID1473345Induction hematopoietic stem cell mobilization in C57BL/6 mouse assessed as increase in CXCR4+ cells in blood at 6 mg/kg, sc measured after 2 hrs by APC-conjugated anti-CXCR4-staining based flow cytometry relative to vehicle control2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID1702401Antagonist activity at CXCR4 in human CD4-positive T cells assessed as inhibition of CXCL12-induced calcium signal incubated for 20 mins by FLIPR assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Structural optimization of aminopyrimidine-based CXCR4 antagonists.
AID265526Effect on copper concentration in Wistar rat brain corpus callosum at 5 mg/kg, iv after 1 hr relative to control2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID710730Cytotoxicity against human PBMC cells by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID358014Antagonist activity at human CXCR4 D171N mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID443574Cytotoxicity against human MT4 cells after 4 days by MTT method2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
AID73060Inhibitory concentration of compound against HIV-1 Ba1 strain in GHOST CCR5 cell line2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID1586096Displacement of [125I]-CXCL12 from human CXCR4 receptor expressed in HEK293T cell membranes after 2 hrs by scintillation counting analysis2019European journal of medicinal chemistry, Jan-15, Volume: 162Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists.
AID1316423Inhibition of PE-conjugated-12G5 anti-CXCR4 antibody binding to CXCR4 in human CEM-CCRF cells preincubated for 30 mins followed by antibody addition by FACS Canto II cytofluorometric analysis2016Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18
Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.
AID358029Antagonist activity at human CXCR4 H281A mutant expressed in U87.CD4 cells assessed as inhibition of CXCL12-induced calcium mobilization2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID525113Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID358038Antiviral activity against HIV1 clinical isolate 10 infected in U87.CD4 cells expressing human CXCR4 D262N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1574049Inhibition of biotinylated TN14003 binding to CXCR4 in human MDA-MB-231 cells preincubated for 10 mins followed by biotinylated-TN14003 addition measured after 30 mins by streptavidin-rhodamine staining based fluorescence microscopic analysis2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and evaluation of 2,5-diamino and 2,5-dianilinomethyl pyridine analogues as potential CXCR4 antagonists.
AID559943Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID559988Inhibition of Mab 12G5 binding to CXCR4 W283A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID525102Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1357124Toxicity in Balb/c mouse model of hypereosinophilia assessed as reduction in spleen weight at 12.6 umol/kg, ip dosed daily 2 hrs before allergen challenge for 3 days and measured 24 hrs after last dose2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia.
AID1742057Inhibition of APC-conjugated anti-human CXCR4 clone 12G5 binding to CXCR4 in human HPBALL cells measured after 3 hrs by FACS analysis
AID358000Displacement of [125I]12G5 antibody from transmembrane domain 5 of human CXCR4 G207F mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358025Antagonist activity at human CXCR4 H281A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID509035Antiviral activity against HIV1 JRCSF infected in human vaginal intraepithelial cells assessed as decrease in viral genomic integration at 1 uM by multiplex PCR assay2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
AID358016Antagonist activity at human CXCR4 A175F mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID408925Displacement of [125I]CXCL12 from CXCR4 in rat IR983F cells2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
AID276977Cytotoxicity against PBMC2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and anti-HIV properties of new hydroxyquinoline-polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains.
AID357992Displacement of [125I]12G5 antibody from extracellular loop 2 of human CXCR4 N176A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358035Antiviral activity against HIV1 clinical isolate 10 infected in U87.CD4 cells expressing human CXCR4 D171N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID559945Antiviral activity against NRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID559989Inhibition of Mab 12G5 binding to CXCR4 I284A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID358010Displacement of [125I]12G5 antibody from transmembrane domain 7 of human CXCR4 E288A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358005Displacement of [125I]12G5 antibody from transmembrane domain 6 of human CXCR4 S263A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID357986Displacement of [125I]12G5 antibody from human wild type CXCR4 expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1702407Antagonist activity at CCR4 in human MDA-MB-231 cells assessed as inhibition of CCL12-mediated chemotaxis at 100 nM after 22 hrs by transwell assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Structural optimization of aminopyrimidine-based CXCR4 antagonists.
AID710732Cytotoxicity against human MT4 cells by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID1742064Antagonist activity at CXCR4 in human MDA-MB-231 cells assessed as inhibition of CXCL12-induced cell migration at 100 nM measured after 24 hrs by crystal violet staining based matrigel invasion assay
AID357991Displacement of [125I]12G5 antibody from extracellular loop 2 of human CXCR4 A175F mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1882264Induction of mitotic arrest in human multiple myeloma cells2022European journal of medicinal chemistry, Feb-05, Volume: 229A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1473346Induction of hematopoietic stem cell mobilization in C57BL/6 mouse assessed as increase in CFU-GM colonies from PBMC at 6 mg/kg, sc administered on day 5 post 100 ug/kg/day G-CSF addition for 4 days measured after 2 hrs post compound dose by colony formin2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID549722Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production at 1 ug/mL after 4 days by ELISA2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.
AID358009Displacement of [125I]12G5 antibody from transmembrane domain 6 of human CXCR4 I259W mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID357999Displacement of [125I]12G5 antibody from transmembrane domain 5 of human CXCR4 G207W mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1383871Inhibition of biotinylated TN14003 binding to CXCR4 in human MDA-MB-231 cells preincubated for 10 mins followed by TN14003 addition measured after 30 mins by rhodamine dye-based microscopic analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives.
AID1720086Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.
AID1383112Displacement of 12G5-CXCL12 from CXCR4 in human HPBALL cells after 3 hrs by FACS analysis2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.
AID443573Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
AID427795Inhibition of HIV1 NL4-3 envelope glycoprotein 120-mediated membrane fusion between virus-transfected african green monkey COS cells and human TZM-bl cells by luciferase-based cell-cell fusion assay in presence of IC95642008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
AID104769Concentration required to cause 50% death of uninfected MT-4 cells1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor.
AID559959Antagonist activity at CXCR4 expressed in CHO cells assessed as inhibition of SDF1-alpha-induced calcium mobilization up to 1 uM by fluorescence assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID559940Antiviral activity against HIV1 R5 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID358039Antiviral activity against HIV1 NL43 infected in U87.CD4 cells expressing human CXCR4 H281A mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID559938Antiviral activity against HIV1 R5X4 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID358023Antagonist activity at human CXCR4 I259W mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID482692Antiviral activity against HIV1 NL4-3 pseudotyped with VSV-G envelope infected in human C8166 cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID393146Antagonist activity at CXCR4 in human Jurkat cells assessed as inhibition of SDF1-induced cell migration2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
AID559980Inhibition of Mab 12G5 binding to CXCR4 D171A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1473289Acute toxicity in sc dosed C57BL/6 mouse assessed as maximum tolerated dose by measuring mortality2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID405229Antiviral activity against HIV1 NL4.3 in human MT4 cells2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
AID1551314Inhibition of CXCR4-mediated chemotaxis in human MDA-MB-231 cells assessed as reduction in CXCL12alpha-induced cell invasion incubated for 22 hrs by hematoxylin/eosin dye-based matrigel assay relative to control2019European journal of medicinal chemistry, Jul-01, Volume: 173Development of CXCR4 modulators based on the lead compound RB-108.
AID1693429Antiviral activity against HIV-1 NL4-3 in human MT-4 cells assessed as virus induced cytopathic effect incubated for 5 days by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.
AID84662Antiretroviral activity against HIV-2 infected HUT-78 cells.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
AID1288223Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay2016European journal of medicinal chemistry, May-23, Volume: 114Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
AID358027Antagonist activity at human CXCR4 T287A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID265523Distribution of copper in Wistar rat brain corpus callosum at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID358018Antagonist activity at human CXCR4 Q200W mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID559941Antiviral activity against HIV1 A018H infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID358032Antiviral activity against HIV1 clinical isolate 10 infected in U87.CD4 cells expressing human wild type CXCR42007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358034Antiviral activity against HIV1 NDK infected in U87.CD4 cells expressing human CXCR4 D171N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID357990Displacement of [125I]12G5 antibody from transmembrane domain 4 of human CXCR4 F174A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID612456Antiviral activity against HIV NL-Lai infected in human TZM-bl cells assessed as inhibition of viral infection at 100 uM treated before viral infection measured after 24 hrs by luciferase assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides.
AID408960Antiviral activity against X4-tropic HIV1 3B assessed as inhibition of viral attachment2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
AID559983Inhibition of Mab 12G5 binding to CXCR4 D262A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1238318Cytotoxicity against human PM1 cells expressing CCR5 by MTT assay in presence of 5 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID559935Antiviral activity against HIV1 NL4-3 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID81801Inhibition of syncytium formation using HIV-1 IIIB strain gaint cell inhibition assay.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
AID265520Distribution of copper per 100 ml of Wistar rat blood at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID559944Antiviral activity against HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1238309Cytotoxicity against human MT4 cells by MTT assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID525106Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID357998Displacement of [125I]12G5 antibody from transmembrane domain 5 of human CXCR4 H203A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID429220Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral replication2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Bis-14-membered ring diketal diamines: synthesis and evaluation of their anti-HIV and anti-tumoral activities.
AID1312694Inhibition of CXCL2alpha-induced invasion of human MDA-MB-231 cells at 100 nM after 22 hrs by hematoxylin/eosin-staining based matrigel assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Symmetrical bis-tertiary amines as novel CXCR4 inhibitors.
AID358033Antiviral activity against HIV1 NL43 infected in U87.CD4 cells expressing human CXCR4 D171N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1720088Cytotoxicity against Human immunodeficiency virus 1 NLAD8 infected in human PM1 cells expressing CCR5 assessed as cell viability measured after 5 days by MTT assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.
AID381449Induction of [125I]SDF1alpha dissociation from CXCR4 expressed in CHOK1 cells by non-equilibrium binding assay2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID1288224Potency index, ratio of JM2763 EC50 to compound EC50 for HIV1 3B infected in human MT4 cells2016European journal of medicinal chemistry, May-23, Volume: 114Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
AID357987Displacement of [125I]12G5 antibody from transmembrane domain 3 of human CXCR4 H113A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358019Antagonist activity at human CXCR4 Q200A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1693430Antiviral activity against HIV-1 NL(AD8) in human PM1/CCR5 cells assessed as virus induced cytopathic effect incubated for 5 days by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.
AID1238310Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID358001Displacement of [125I]12G5 antibody from transmembrane domain 6 of human CXCR4 Y255A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1238313Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID393145Displacement of [125I]SDF1alpha from CXCR4 in human HL60 cells2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
AID358021Antagonist activity at human CXCR4 Y255A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1720087Antiviral activity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity measured after 5 days by MTT assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.
AID358044Antiviral activity against HIV1 clinical isolate 10 infected U87.CD4 cells expressing human CXCR4 E288A mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID429223Cytotoxicity against human CEM-SS cells by MTT assay2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Bis-14-membered ring diketal diamines: synthesis and evaluation of their anti-HIV and anti-tumoral activities.
AID303363Antagonist activity at CXCR4 in human U87 cells assessed as inhibition of SDF1-induced modulation of cAMP production at 1000 nM by TR-FRET assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Discovery of small molecule CXCR4 antagonists.
AID358028Antagonist activity at human CXCR4 E288A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID104777Concentration required to reduce the viability of mock infected cells by 50%1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams.
AID1242372Antiviral activity against VSV by VSV-G pseudovirus assay2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.
AID381447Inhibition of migration of human CD4+ lymphoblasts towards SDF1 by chemotaxis assay2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID381443Displacement of [125I]SDF1alpha from CXCR4 expressed in CHOK1 cells2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID429221Cytotoxicity against human MT4 cells by MTT assay2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Bis-14-membered ring diketal diamines: synthesis and evaluation of their anti-HIV and anti-tumoral activities.
AID1473314Induction of hematopoietic stem cell mobilization in C57BL/6 mouse PBMC assessed as increase in CFU-GM colonies at 1 mg/kg, sc administered on day 5 post G-CSF addition measured after 2 hrs post dose by colony forming assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID710729Antagonist activity against CXCR5 expressed in U87.CD.CXCR5 cells assessed as inhibition of CCL3L1-induced calcium signaling incubated for 10 mins by FLIPR2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1312693Displacement of biotinylated TN14003 from CXCR4 CXCL12 binding domain in human MDA-MB-231 cells preincubated for 10 mins followed by biotinylated TN14003 addition measured after 30 mins using streptavidin-conjugated rhodamine by fluorescence microscopic a2016European journal of medicinal chemistry, Aug-08, Volume: 118Symmetrical bis-tertiary amines as novel CXCR4 inhibitors.
AID559986Inhibition of Mab 12G5 binding to CXCR4 V280A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1507422Inhibition of CXCR4-mediated chemotaxis in human MDA-MB-231 cells assessed as inhibition of CXCL12alpha-induced cell invasion at 100 nM after 22 hrs by hematoxylin/eosin dye-based matrigel assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study.
AID105157Effective concentration against HIV-2(ROD) replication in MT-4 cells1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams.
AID279188Inhibition of HIV1 92TH594 infected CXCR4+/CD4+/U87 cells to assess co-receptor tropism as luciferase activity2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.
AID1442774Antiviral activity against HIV1 HXB2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral entry treated 1 hr post infection measured after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID265525Increase in copper concentration in Wistar rat brain cortex at 5 mg/kg, iv after 1 hr relative to control2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID358006Displacement of [125I]12G5 antibody from transmembrane domain 7 of human CXCR4 H281A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1238315Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID317104Inhibition of mouse neuroblast cell migration from subventricular zone tissue explants at 63 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Discovery of new small molecules that influence neuroblast cell migration from the subventricular zone.
AID1473306AUC (0 to 4 hrs) in C57BL/6 mouse at 6 mg/kg, sc measured up to 4 hrs post dose by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID358022Antagonist activity at transmembrane domain 6 of human CXCR4 I259A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID499099Antiviral activity against HIV1 UG273 clade A, R5 in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID358733Antiviral activity against HIV1 clinical isolate 10 infected in U87.CD4 cells expressing human CXCR4 D171ND262N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358017Antagonist activity at human CXCR4 V196A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1812649Anti-HIV activity against HIV-1 Ba-L infected in PHA-stimulated PBMC expressing CCR5 assessed as inhibition of virus-indued cytopathogenic effect measured after 10 days by ELISA
AID358020Antagonist activity at human CXCR4 H203A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358002Displacement of [125I]12G5 antibody from transmembrane domain 6 of human CXCR4 Y256A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID559987Inhibition of Mab 12G5 binding to CXCR4 H281A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1383873Inhibition of CXCR4 in human MDA-MB-231 cells assessed as decrease in CXCL12-dependent cell invasion at 100 nM after 22 hrs by hematoxylin and eosin staining based matrigel assay relative to control2018European journal of medicinal chemistry, Apr-25, Volume: 150Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives.
AID279334Inhibition of X4 HIV1 replication at 5 uM2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
AID525104Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID279191Inhibition of HIV1 JRCSF infected CCR5+/CD4+/U87 cells to assess co-receptor tropism as luciferase activity2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.
AID358015Antagonist activity at human CXCR4 F172A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID357993Displacement of [125I]12G5 antibody from extracellular loop 2 of human CXCR4 D182A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1238314Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID279190Inhibition of HIV1 HXB2 infected CXCR4+/CD4+/U87 cells to assess co-receptor tropism as luciferase activity2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.
AID499102Antiviral activity against HIV1 DJ259 in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID358042Antiviral activity against HIV1 NL43 infected in U87.CD4 cells expressing human CXCR4 E288A mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1595664Competitive binding affinity to CXCR4 in human SupT1 cells incubated for 40 mins by 12G5 antibody based fluorescence analysis2019European journal of medicinal chemistry, Jun-15, Volume: 172High affinity CXCR4 inhibitors generated by linking low affinity peptides.
AID276975Antiviral activity against HIV1 LAV in PBMC2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and anti-HIV properties of new hydroxyquinoline-polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains.
AID1288222Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells2016European journal of medicinal chemistry, May-23, Volume: 114Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
AID357994Displacement of [125I]12G5 antibody from extracellular loop 2 of human CXCR4 D187A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID525108Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID265522Distribution of copper in Wistar rat brain cortex at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID1902006Antagonist activity at CXCR4 receptor in SDF-1alpha-stimulated human SUP-T1 cells measured by calcium mobilization assay2022European journal of medicinal chemistry, Mar-05, Volume: 231A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist.
AID358037Antiviral activity against HIV1 NL43 infected in U87.CD4 cells expressing human CXCR4 D262N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID358043Antiviral activity against HIV1 NDK infected in U87.CD4 cells expressing human CXCR4 E288A mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID105156Effective concentration against HIV-1(IIIB) replication in MT-4 cells1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams.
AID358031Antiviral activity against HIV1 NDK infected in U87.CD4 cells expressing human wild type CXCR42007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1902008Binding affinity to CXCR4 (unknown origin) expressed in CHO cells measured by 12G5 competitive binding method2022European journal of medicinal chemistry, Mar-05, Volume: 231A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist.
AID1473311Induction of hematopoietic stem cell mobilization in C57BL/6 mouse assessed as induction of movement of HSCs and EPCs into peripheral circulation at 6 mg/kg, sc measured after 2 hrs by flow cytometric analysis relative to control2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID499097Antiviral activity against HIV1 BZ167 in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID1238316Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 10 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID559978Inhibition of Mab 12G5 binding to CXCR4 V112A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1383113Antagonist activity at CXCR4-mediated chemotaxis in human MDA-MB-231 cells assessed as inhibition of CXCL12-induced cell invasion at 100 nM after 24 hrs by crystal violet staining-based microscopic matrigel assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.
AID559981Inhibition of Mab 12G5 binding to CXCR4 D181A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1595677Competitive binding affinity to CXCR4 receptor (unknown origin) expressed in CHO cells incubated for 40 mins by 12G5 antibody based fluorescence analysis2019European journal of medicinal chemistry, Jun-15, Volume: 172High affinity CXCR4 inhibitors generated by linking low affinity peptides.
AID509037Antiviral activity against HIV1 isolate M1 infected in human vaginal intraepithelial cells assessed as decrease in viral genomic integration at 1 uM after 48 hrs by multiplex PCR assay2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
AID1238317Antiviral activity against macrophage-tropic HIV1 NL(AD8) infected in human PM1 expressing CCR5 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID1435833Inhibition of CXCR4/CXCL12 interaction-mediated chemotaxis in human MDA-MB-231 cells assessed as inhibition of cell invasion at 100 nM after 22 hrs by hematoxylin/eosin dye-based matrigel assay relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.
AID358013Antagonist activity at human CXCR4 L120F mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID381452Antagonist activity at CXCR4 expressed in CHOK1 cells assessed as inhibition of SDF1-alpha-induced signaling by aequorin-based assay2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID559976Inhibition of Mab 12G5 binding to wild type CXCR4 expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID357996Displacement of [125I]12G5 antibody from transmembrane domain 5 of human CXCR4 Q200W mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1442802Antiviral activity against HIV1 HXB2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral entry treated 2 to 4 hrs post infection measured after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID559985Inhibition of Mab 12G5 binding to CXCR4 E277A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID559979Inhibition of Mab 12G5 binding to CXCR4 H113A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID559990Inhibition of Mab 12G5 binding to CXCR4 E288A/L290A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID45542Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID1702408Antagonist activity at CXCR4 in human HPBALL cells assessed as inhibition of APC-conjugate clone 12G5 antibody signal incubated for 3 hrs by flow cytometric analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187Structural optimization of aminopyrimidine-based CXCR4 antagonists.
AID276976Antiviral activity against HIV1 BaL in PBMC2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Synthesis and anti-HIV properties of new hydroxyquinoline-polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains.
AID559942Antiviral activity against HIV1 A018G infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID358024Antagonist activity at human CXCR4 D262N mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1473305Half life in C57BL/6 mouse at 6 mg/kg, sc measured up to 4 hrs post dose by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID1473304Cmax in C57BL/6 mouse at 6 mg/kg, sc measured up to 4 hrs post dose by LC-MS/MS analysis2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID1238311Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID358004Displacement of [125I]12G5 antibody from transmembrane domain 6 of human CXCR4 D262N mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID559982Inhibition of Mab 12G5 binding to CXCR4 H203A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1852184Agonist activity at human ACKR3 expressed in HEK293T cells assessed as beta-arrestin recruitment incubated for 30 mins by BRET assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
AID152965Concentration of compound causing 50% death of uninfected cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID358731Antiviral activity against HIV1 NL43 infected in U87.CD4 cells expressing human CXCR4 D171N/D262N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID499095Antiviral activity against HIV1 NL4.3 in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID525110Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID265521Distribution of copper in Wistar rat CSF at 5 mg/kg, iv after 1 hr2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID1501130Antagonist activity at CXCR4 (unknown origin)2017European journal of medicinal chemistry, Oct-20, Volume: 139An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.
AID358007Displacement of [125I]12G5 antibody from transmembrane domain 7 of human CXCR4 I284A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID232753Selectivity index is the ratio of EC50 and CC50 in MT-4 cells1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor.
AID1238312Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
AID358041Antiviral activity against HIV1 clinical isolate 10 infected in U87.CD4 cells expressing human CXCR4 H281A mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1902011Antagonist activity at CXCR4 receptor in human SUP-T1 assessed as inhibition of SDF-1alpha-induced CXCR4 internalization at 0.1 to 10 uM and measured by flow cytometry analysis2022European journal of medicinal chemistry, Mar-05, Volume: 231A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist.
AID1242368Inhibition of CXCR4 in human Jurkat cells assessed as reduction in HIV-Nef-M1-induced mitochondrial membrane depolarization at 0.01 to 100 uM by JC1 dye based fluorescence depolarization assay2015ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.
AID358026Antagonist activity at human CXCR4 I284A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID105180Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID710731Antiviral activity against X4 HIV1 NL4.3 infected in human PBMC assessed as inhibition of viral replication pre-incubated for 30 mins measured 5 days post infection by MTT assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID559977Inhibition of Mab 12G5 binding to CXCR4 V99A mutant expressed in HEK293 cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID358036Antiviral activity against HIV1 NDK infected in U87.CD4 cells expressing human CXCR4 D262N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID707908Lipophilicity, log P of the compound2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID381448Induction of [125I]MCP1 dissociation from CCR2 expressed in CHOK1 cells by non-equilibrium binding assay2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID525105Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID429222Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as inhibition of viral replication2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Bis-14-membered ring diketal diamines: synthesis and evaluation of their anti-HIV and anti-tumoral activities.
AID84657Cellular cytotoxicity against HUT-78 cells.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
AID565584Binding affinity to IQNI7 pocket of HIV1 3B gp41 at 1 uM after 30 mins by SPR assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
AID559937Antiviral activity against HIV1 89.6 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1574051Antiinflammatory activity in C57Bl/6J mouse assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip treated for 2 days measured 2 hrs post last dose by caliper method relative to control2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and evaluation of 2,5-diamino and 2,5-dianilinomethyl pyridine analogues as potential CXCR4 antagonists.
AID559946Antiviral activity against NNRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1357121Anti-inflammatory activity in Balb/c mouse model of hypereosinophilia assessed as inhibition of eosinophil infiltration at 12.6 umol/kg, ip dosed 2 hrs before allergen challenge2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia.
AID105136Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor.
AID357989Displacement of [125I]12G5 antibody from transmembrane domain 4 of human CXCR4 F172A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1477232Antagonist activity at GFP-tagged CXCR4 (unknown origin) expressed in CHO cells assessed as inhibition of CXCL12-induced receptor internalization at 10 nM preincubated for 45 mins followed by CXCL12 induction measured after 0.5 to 24 hrs by confocal micro2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.
AID499100Antiviral activity against HIV1 US2 clade B, R5 in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID381453Antagonist activity at CCR2/CXCR4 expressed in CHOK1 cells assessed as inhibition of SDF1-alpha-induced signaling by aequorin-based assay2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1693431Cytotoxicity against in human MT-4 after 5 days by MTT assay2021Bioorganic & medicinal chemistry, 01-15, Volume: 30Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.
AID1630882Binding affinity to CXCR4 (unknown origin) expressed in CHO cells measured after 40 mins by 12G5 antibody competition assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.
AID707875Binding affinity to CXCR42012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID559939Antiviral activity against HIV1 JRCSF infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1383114Antagonist activity at CXCR4 in human CD4+ T cells assessed as inhibition of CXCL12-mediated cytosolic calcium level preincubated with compounds followed by CXCL12 stimulation by calcium 4 dye-based FLIPR assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.
AID1586106Competitive antagonist activity at human CXCR4 receptor expressed in HEK293T cells co-expressing galphai1 assessed as inhibition of CXCL12-induced receptor activation up to 100 uM preincubated for 30 mins followed by CXCL12 addition and measured after 20 2019European journal of medicinal chemistry, Jan-15, Volume: 162Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists.
AID559936Antiviral activity against HIV1 X4 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1473324In vivo induction of WBC mobilization in C57BL/6 mouse at 6 mg/kg, sc measured after 2 hrs2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
AID358732Antiviral activity against HIV1 NDK infected in U87.CD4 cells expressing human CXCR4 D171ND262N mutant2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID710734Antagonist activity against CXCR4 expressed in U87.CD.CXCR4 cells assessed as inhibition of CXCL12-induced calcium signaling incubated for 10 mins by FLIPR2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID105021Concentration of compound causing 50% death of uninfected cells2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity.
AID357997Displacement of [125I]12G5 antibody from transmembrane domain 5 of human CXCR4 Q200A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID265524Decrease in copper concentration in Wistar rat CSF at 5 mg/kg, iv after 1 hr relative to control2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1586098Displacement of [125I]-CXCL12 from human CXCR4 receptor expressed in HEK293T cell membranes at 63 uM after 2 hrs by scintillation counting analysis relative to IT1t2019European journal of medicinal chemistry, Jan-15, Volume: 162Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists.
AID1574050Inhibition of CXCR4-mediated chemotaxis in human MDA-MB-231 cells assessed as reduction in CXCL12alpha-induced cell invasion at 100 nM after 22 hrs by hematoxylin/eosin dye-based matrigel assay relative to control2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Synthesis and evaluation of 2,5-diamino and 2,5-dianilinomethyl pyridine analogues as potential CXCR4 antagonists.
AID1435831Displacement of biotinylated-TN14003 from CXCR4 in human MDA-MB-231 cells assessed as reduction in fluorescence preincubated for 10 mins followed by biotinylated-TN14003 addition measured after 30 mins by streptavidin-rhodamine staining based microscopic 2017European journal of medicinal chemistry, Jan-27, Volume: 126Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.
AID559966Inhibition of Mab 12G5 binding to CXCR4 expressed in human MOLT4 cells at 1000 nM measured post drug washout by FACS analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1383288Antiviral activity against HIV1 3B2018European journal of medicinal chemistry, Apr-10, Volume: 149The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.
AID525114Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID358011Antagonist activity at human wild type CXCR4 expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID499101Antiviral activity against HIV1 ETH2220 in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID358012Antagonist activity at human CXCR4 H113A mutant expressed in COS7 cells coexpressing G protein Gqi4myr assessed as inhibition of CXCL12-induced phosphatidylinositol turnover2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID1288221Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay2016European journal of medicinal chemistry, May-23, Volume: 114Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
AID1519443Competitive binding affinity at CXCR4 in human MDA-MB-231 cells preincubated for 10 mins followed by biotinylated TN14003 addition further incubated for 30 mins by fluorescence microscopy2020European journal of medicinal chemistry, Jan-01, Volume: 185Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
AID565589Binding affinity to IQNI7 pocket of HIV1 3B gp41 assessed as induction of conformational change of IQNI7 by real-time plasmon resonance assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
AID559965Inhibition of Mab 12G5 binding to CXCR4 expressed in human MOLT4 cells at 1000 nM by FACS analysis2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1519444Inhibition of CXCR4-mediated chemotaxis in human MDA-MB-231 cells assessed as reduction in CXCL12alpha-induced cell invasion after 22 hrs by hematoxylin/eosin dye-based matrigel assay relative to control2020European journal of medicinal chemistry, Jan-01, Volume: 185Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
AID1477220Inhibition of anti-CXCR4 PE antibody clone 12G5 binding to CXCR4 in human CCRF-CEM cells preincubated for 30 mins followed by anti-CXCR4 PE antibody clone 12G5 addition measured after 30 mins by flow cytometric method2017Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.
AID381450Induction of [125I]MCP1 dissociation from CCR2/CXCR4 expressed in CHOK1 cells by non-equilibrium binding assay2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID1902009Antagonist activity at CXCR4 receptor in human SUP-T1 cells assessed as reduction in SDF-1alpha-stimulated cell migration and measured by CellTiter-96 assay2022European journal of medicinal chemistry, Mar-05, Volume: 231A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist.
AID1357123Toxicity in Balb/c mouse model of hypereosinophilia assessed as reduction in body weight at 12.6 umol/kg, ip dosed daily 2 hrs before allergen challenge for 3 days and measured 24 hrs after last dose2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia.
AID559947Antiviral activity against PI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID525112Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID559951Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID84661Antiretroviral activity against HIV-1 infected HUT-78 cells.1995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.
AID499096Antiviral activity against HIV1 Ba-L in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID1551312Competitive inhibition of biotinylated TN14003 binding to CXCR4 in human MDA-MB-231 cells preincubated for 10 mins followed by biotinylated-TN14003 addition measured after 30 mins by streptavidin-rhodamine staining based fluorescence microscopic analysis2019European journal of medicinal chemistry, Jul-01, Volume: 173Development of CXCR4 modulators based on the lead compound RB-108.
AID381445Displacement of [125I]SDF1alpha from CCR2/CXCR4 expressed in CHOK1 cells2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID565588Inhibition of PIE7 binding to HIV1 3B gp41 at 1 uM after 30 mins by ELISA2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
AID710727Inhibition of anti-CXCR4 mAbs clone 12G5 binding to CXCR4 in human SUPT1 cells incubated for 15 mins by FACS2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID358008Displacement of [125I]12G5 antibody from transmembrane domain 7 of human CXCR4 T287A mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID19209Partition coefficient (logP)1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor.
AID357988Displacement of [125I]12G5 antibody from transmembrane domain 4 of human CXCR4 D171N mutant expressed in COS7 cells2007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID612457Antiviral activity against HIV NL-Lai infected in human TZM-bl cells assessed as inhibition of viral infection at 100 uM treated 4 hrs after viral infection measured after 24 hrs by luciferase assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID358030Antiviral activity against HIV1 NL43 infected in U87.CD4 cells expressing human wild type CXCR42007The Journal of biological chemistry, Sep-14, Volume: 282, Issue:37
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
AID525109Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1742058Antagonist activity at CXCR4 in human CD4-positive T cells assessed as inhibition of CXCL12-induced cytosolic calcium flux preincubated for 20 mins followed by CXCL12 addition by calcium 4 dye based FLIPR TETRA analysis
AID381444Displacement of [125I]MCP1 from CCR2/CXCR4 expressed in CHOK1 cells2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
AID499098Antiviral activity against HIV1 strain I-2496 in human PBMC assessed as p24 antigen level by ELISA2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
AID408924Displacement of [125I]CXCL12 from CXCR4 in human CEM cells2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
AID509043Antiviral activity against HIV1 JRCSF infected in human vaginal epithelium assessed as viral genomic integration by titration assay relative to control2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
AID1507420Inhibition of biotinylated TN14003 binding to CXCR4 in human MDA-MB-231 cells assessed as reduction in fluorescence preincubated for 10 mins followed by biotinylated-TN14003 addition measured after 30 mins by streptavidin-rhodamine staining based immunofl2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study.
AID509032Antiviral activity against HIV1 JRCSF infected in human vaginal intraepithelial cells assessed as decrease in viral genomic integration at 1 uM by singleplex PCR assay2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
AID1720085Antiviral activity against Human immunodeficiency virus 1 NLAD-8 infected in human PM1 cells expressing CCR5 assessed as reduction in virus-induced cytopathogenicity measured after 5 days by MTT assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.
AID710735Inhibition of CXCL-12'AF647 binding to CXCR4 in human SUPT1 cells incubated for 15 mins by FACS2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
AID559950Antiviral activity against multidrug resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346774Human CCR4 (Chemokine receptors)2006Biochemical pharmacology, Aug-28, Volume: 72, Issue:5
Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.
AID1346861Human ACKR3 (Chemokine receptors)2009Molecular pharmacology, May, Volume: 75, Issue:5
AMD3100 is a CXCR7 ligand with allosteric agonist properties.
AID1346861Human ACKR3 (Chemokine receptors)2010The Journal of biological chemistry, Dec-03, Volume: 285, Issue:49
The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
AID1346821Human CXCR4 (Chemokine receptors)2002The Journal of biological chemistry, Jul-05, Volume: 277, Issue:27
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,293)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's26 (2.01)18.2507
2000's254 (19.64)29.6817
2010's856 (66.20)24.3611
2020's157 (12.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.01 (24.57)
Research Supply Index7.26 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index100.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials113 (8.61%)5.53%
Reviews108 (8.23%)6.00%
Case Studies41 (3.13%)4.05%
Observational7 (0.53%)0.25%
Other1,043 (79.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]